Our Bureau

Hyderabad , July 12

AUROBINDO Pharma Ltd has announced that it was granted the tentative approval for the abbreviated new drug application (ANDA) on a drug lamivudine and zidovudine tablets, 150 mg/300 mg with combination.

In a press release here on Tuesday, the company said this is another significant achievement for it in terms of formulation technology.

The drug is the first generic version of GlaxoSmithKline Plc's combination AIDS drug Combivir.

The company said the USFDA approval would enable it to participate in President's Emergency Plan for AIDS Relief program.

The drug under consideration is one of the popular combinations prescribed by doctors around the world and is one of the largest sellers in the ARV (anti-retroviral) segment.

Lamivudine and zidovudine are in the class of drugs called nucleoside reverse transcriptase inhibitors, which help keep the AIDS virus from reproducing.

This fixed-dose combination anti-retroviral drug is intended for use with other anti-retroviral agents for the treatment of HIV-1 infection, the release said.